Evidence map›Paper›PMID 34837001›Full record

ArticleScientific reports2021

A SARS-CoV-2 antigen rapid diagnostic test for resource limited settings.

Erica Frew, Douglas Roberts, Shelly Barry, Matthew Holden, Amanda Restell Mand, Emily Mitsock, Enqing Tan, Wei Yu, Johan Skog

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Erica Frew *Bio-Techne, Devens, MA, USA. erica.frew@bio-techne.com.
Douglas Roberts *Exosome Diagnostics, A Bio-Techne Brand, Waltham, MA, USA.
Shelly BarryBio-Techne, Devens, MA, USA.
Matthew HoldenBio-Techne, Devens, MA, USA.
Amanda Restell MandBio-Techne, Devens, MA, USA.
Emily MitsockExosome Diagnostics, A Bio-Techne Brand, Waltham, MA, USA.
Enqing TanBio-Techne, Devens, MA, USA.
Wei YuExosome Diagnostics, A Bio-Techne Brand, Waltham, MA, USA.
Johan SkogExosome Diagnostics, A Bio-Techne Brand, Waltham, MA, USA.
R&D Systems (United States) · USExosome Diagnostics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19 disease. RT-qPCR has been the primary method of diagnosis; however, the required infrastructure is lacking in many developing countries and the virus has remained a global challenge. More inexpensive and immediate test methods are required to facilitate local, regional, and national management strategies to re-open world economies. Here we have developed a SARS-CoV-2 antigen test in an inexpensive lateral flow format to generate a chromatographic result identifying the presence of the SARS-CoV-2 antigen, and thus an active infection, within a patient anterior nares swab sample. Our 15-min test requires no equipment or laboratory infrastructure to administer with a limit of detection of 2.0 × 10

Indexed as

Antigens, ViralCOVID-19COVID-19 Serological TestingSARS-CoV-2Sensitivity and SpecificityHumansRapid Diagnostic TestsResource-Limited SettingsAntigens, Viral

Identifiers

PMID34837001
PMCPMC8626481
OpenAlexW3182034077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.